Kornimate/medical-research-clean huggingface dataset:
positive pressure ventilation through a laryngeal mask airway in pediatrics

Conditions: Pediatric; Anesthesia

Summary: the investigators aimed to investigate effects of intubation and laryngeal mask airway usage in pediatrics during laparoscopic inguinal hernia repair.

considering blood gas analysis, end tidal carbon dioxide measurements and airway changes, the investigators aimed to investigate effects of intubation and laryngeal mask airway usage in pediatrics during laparoscopic inguinal hernia repair in this study.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status i, being scheduled to undergo laparoscopic inguinal hernia. exclusion criteria: * patients, who did not want to participate, patients with severe airway deformities, patients having increased gastroesophageal regurgitation risk, reactive airway hiatal hernia, peripheric vascular disease, mental retardation, neuropsychiatric illness or an lung infection during the last 6 weeks.
endoscopic ultrasound evaluation of the common bile duct in patients with obstructive jaundice due to bilio-pancreatic malignancies (ecco trial)

Conditions: Obstructive Jaundice; Bilio-pancreatic Tumor

Summary: to assess the size of the common bile duct in a large cohort of patients with jaundice following a malignant tumor of the head of the pancreas or the distal bile duct receiving a diagnostic ea for biopsy and / or for evaluation of tissue resectability.


Eligibility criteria:
inclusion criteria: * patients with jaundice and an injury to the head of the pancreas recommended for eus-guided tissue acquisition or staging * patients with jaundice and distal cbd lesion suggestive of cholangiocarcinoma or vater's ampulla carcinoma recommended for eus-guided tissue acquisition or staging * serum bilirubin level ≥ 3 mg / dl * age ≥ 18 years old * subject affiliated or beneficiary of a social security scheme. * subject having been informed of this study and having given his no objection exclusion criteria: * presence of altered anatomy due to previous gastric surgery (billroth ii or roux-en-y anastomosis) * sphincterotomy performed previously, plastic biliary stent or metal stent placement * percutaneous drainage of the bile ducts performed previously * pregnant, breastfeeding or parturient woman * protected patients: adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision; hospitalized without consent.
using a mhealth app to improve quality-of-life outcomes in black prostate cancer survivors

Conditions: Prostate Cancer

Summary: the goal of this clinical trial is to ensure that the mobile health application for black patients with prostate cancer (either actively undergoing treatment or survivors) is usable and acceptable to patients, get feedback about how to improve the app and assess its usefulness in examining their quality of life.

the purpose of this study is to test the effectiveness of a culturally appropriate and specific mobile app for ethnically diverse black men with prostate cancer (either those actively undergoing treatment or survivors) to empower them to be active participants in their care. this app will provide 1) relevant information/education about prostate cancer-specific to black men; 2) symptoms monitoring - allowing participants to report difficulties and prompting providers to respond to concerns; and 3) testimonials from other patients with shared experiences. all participants will be asked to complete surveys online when they start and then again at 3, 6, 9, and 12 months. a subset of randomized participants will be provided access to this app, which they will be asked to use at home for 12 months. the app users will answer daily surveys about their symptoms and activities as well as weekly mood assessments for 3 months. at the end of the 12 months, interviews will be conducted to receive feedback regarding the app.

Eligibility criteria:
inclusion criteria: - ethnically-diverse black prostate cancer (cap) survivors who are either native-born, caribbean-born, or african-born, within the early phase of their cap survivorship journey (defined as within the first five years after diagnosis). exclusion criteria: * men from other races. * men who have never been diagnosed with cap * men who have the inability to speak english * men who do not own a smartphone * black cap survivors who are over 5 years since the time of diagnosis

Keywords: mhealth black men black survivors native-born black man african-born black man caribbeanborn black man
clinical study to evaluate the efficacy and safety of dsxs in patients with mild to moderate plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the purpose of this study is to evaluate the therapeutic efficacy and safety of dsxs compared to a placebo (vehicle) in patients with mild to moderate plaque psoriasis.

to evaluate the therapeutic efficacy and safety of dsxs topical spray, 0.15% (taro pharmaceuticals, u.s.a., inc.) compared to a placebo (vehicle) spray (taro pharmaceuticals, u.s.a., inc.) in patients with mild to moderate plaque psoriasis.

Eligibility criteria:
inclusion criteria: * male and non-pregnant females, 12 years of age or older, with a confirmed diagnosis of mild to moderate plaque psoriasis exclusion criteria: * patient is\< 12 years old.
acupuncture-assisted-anesthesia to improve postoperative outcome after digestive surgery in elderly patients

Conditions: Postoperative Complications; Surgery

Summary: the investigators assume that transcutaneous electric acupoint stimulation (teas) pretreatment may activate the endogenous protective mechanism, as a result protect the patients against subsequent surgical stress pregnancy. and teas may induce the production of endogenous analgesic transmitters, so develop an anesthetic-sparing effect. the investigators believe this intervention will reduce the subsequent incidence, duration and severity of organ dysfunction, possibly reducing the morbidity, even mortality. so in this study, the investigators hypothesize that teas before anesthesia and during surgery would decrease the morbidity and mortality of postoperative complications in 30 days after digestive surgery in elderly patients .

patients older than 65 years old are at higher risk of postoperative morbidity and mortality. with the increasing number of old patients scheduled for digestive surgery, exploring methods to decrease postoperative morbidity is very important. noninvasive methods may be easier to clinically use. transcutaneous electric acupoint stimulation (teas)has been proved to decrease need for general anesthetics during anesthesia, and to alleviate systemic inflammatory response. considering the morbidity and mortality after surgery is closely related to use of anesthetics and inflammatory response,teas may be a good selection for improving postoperative outcomes.among the postoperative complications, pulmonary complication and systemic inflammatory response syndrome is with higher incidence, so we will focus on these two complications in our study.

Eligibility criteria:
inclusion criteria: * provide written informed consent * age ≥65 years of age * elective digestive surgery under general anesthesia exclusion criteria: * asa(american society of anesthesiologists) status\> ⅲ * patients undergoing surgery within 12 h of admission to hospital * patients undergoing surgery of the chest * patients suffered from neurologic disorder or impaired mental state * patients with contraindications to the use of electro-acupuncture, such as skin damage or infection at the acupoints * patients with experience of transcutaneous electrical stimulation treatment

Keywords: transcutaneous electric acupoint stimulation elderly patients
study of the electrocardiographic effects of ta-8995

Conditions: Dyslipidaemia

Summary: a study in healthy males and females to see if a high single dose of ta-8995 has an effect on the ecg qtcf interval.


Eligibility criteria:
inclusion criteria: * healthy male or females of non-child bearing potential exclusion criteria: * receiving any other drug therapy * clinically significant medical history * abnormal ecgs or vital signs
randomized controlled trial of narrative exposure therapy compared to treatment as usual for traumatized refugees

Conditions: Posttraumatic Stress Disorder

Summary: in this study we want to compare narrative exposure therapy to treatment as usual for traumatized refugees and asylum seekers in the mid- norway region. clinicians in psychiatric outpatient clinics will deliver the two conditions to asylum seekers and refugees that qualifies for posttraumatic stress disorder. we will investigate if refugees and asylum seekers will improve more with narrative exposure therapy or treatment as usual, and if there will be any differences between improvement for asylum seekers compared to improvement for refugees with residential status.

narrative exposure therapy (net) will in a randomized controlled trial be compared to treatment as usual(tau) for traumatized refugees and asylum seekers in the mid- norway region. clinicians in psychiatric outpatient clinics in the region will deliver the two conditions to asylum seekers and refugees that qualifies for posttraumatic stress disorder. each patient will receive 10 sessions of either net or tau. assessment tools in the study will be mini international neuropsychiatric interview, clinician administered ptsd scale and the hamilton rating scale for depression. exclusion criteria will be psychosis, substance abuse and serious suicidal ideations. the age group in focus will be adults of 18 years or more. refugees and asylum seekers from all countries will be accepted in the study, and there will be used qualified interpreters if the refugees do not speak english or norwegian fluently.

Eligibility criteria:
inclusion criteria: * refugee or asylum seeker * posttraumatic stress disorder diagnosis according to the dsm-iv criteria exclusion criteria: * psychosis * substance abuse * serious suicidal ideations

Keywords: ptsd trauma treatment refugees randomized controlled
four-limb blood pressures in infants with high risk of congenital malformation of aorta

Conditions: Congenital Heart Disease in Children; Coarctation of Aorta; Interrupted Aortic Arch; Hypoplasia of Aorta; Blood Pressure

Summary: pulse oximetry screening (pos) for critical congenital heart diseases (cchd) could identify 90% of these infants. however, this approach is not designed to detect cardiac defects without hypoxemia, especially congenital malformations of aorta (cmoa). more than 60% of cmoa was late diagnosed. infants with cmoa were supposed to present with blood pressure (bp) gradient between four limbs. but a large sample size retrospective study of four-limb bp screening showed a negative result. the possible reason is that this study ran in population with a very low risk of cmoa. whether four-limb bps measurement could be used in infants with high risk of congenital malformation of aorta is still to be determined. the investigators retrospectively collected four-limb bps, which was prospectively measured, in infants with high risk of cmoa. these data were divided into two groups, the discovery group and the validation group. the best cutoff of four-limb bp gradient was generated by youden index. the bp gradients by age were analyzed. pre-operative hypotension and post-operative hypertension were also analyzed.


Eligibility criteria:
inclusion criteria: * infants admitted to the guangdong provincial people's hospital between january 1st, 2013 and december 31st, 2019, who were suspected as having congenital heart disease, were enrolled in the study. exclusion criteria: * infants without four-limb blood pressures measurement or without echocardiogram and cardiac computed tomography results were excluded.

Keywords: congenital heart disease coarctation of aorta interrupted aortic arch hypoplasia of aorta blood pressure screening
glucose control in hematopoetic stem cell transplant

Conditions: Hyperglycemia; Hematopoietic Stem Cell Transplantation

Summary: to determine whether intensive glucose control results in improved mortality and reduced hospital stay length by performing a randomized trial of intensive glucose management (blood glucose goal 110 mg/dl) using continuous iv insulin and glucose vs. non-intensive glucose management (goal 200 mg/dl)

to determine whether there are fewer infections, days without a fever, days on antibiotics given for an infection and time to marrow engraftment are improved by intensive glucose management; and to determine whether there is evidence of a reduction in measures of inflammation in patients randomized to intensive glucose management and whether reduction of inflammation is associated with outcome.

Eligibility criteria:
inclusion criteria: * patients older than 18 * must meet standard criteria for hsct * if patient is known diabetic at admit the may be maintained on home sulfonylurea and insulin if randomized to the conventional arm exclusion criteria: * if on intensive arm patient must stop all oral hyperglycemic meds

Keywords: hyperglycemia hematopoietic stem cell transplantation bone marrow transplant high blood sugar
development of novel psychological assessment tools and anxiety intervention for phenylketonuria

Conditions: Phenylketonurias

Summary: while previous pku intervention research has largely focused on pharmacological treatment of elevated phe levels, the adaptation of evidence-based psychosocial therapy holds promise for addressing cognitive and psychological symptoms and significantly improving quality of life. study goals include: (1) to demonstrate the efficacy and feasibility of a short-term skills-based intervention (show me first) for anxiety and depression in adolescents with pku, and (2) to further establish the psychometric validity of novel assessment measures recently developed by the investigators that utilize ecological momentary assessment (ema) to capture "in the moment" neurocognitive and psychological function. the investigators propose to conduct a randomized controlled trial wherein 30 adolescents with pku will be randomized to either an immediate intervention group or wait-list/delayed intervention group.

a sample of 30 adolescents (age 10-17) with pku and a history of elevated anxiety and/or depression symptomatology will be recruited to participate in a randomized control trial. following screening and informed consent, participants will be randomized to an immediate intervention group (n=15) or wait-list/delayed intervention group (n=15). participants will receive the 10-week show me first program for treatment of anxiety and depression. participants will complete extensive psychological and neurocognitive evaluations at three timepoints: weeks 0, 11, and 22. the assessments and intervention will all be administered remotely via secure videoconference and cell-phone based applications.

Eligibility criteria:
inclusion criteria: * youth 10-17 years old and at least one parent/guardian * formal diagnosis of pku (as confirmed/reported by caregiver): identified by newborn screening with pku as evidenced by a blood phe level ≥ 360μmol/l; received treatment within the first 30 days of life. * interest in receiving a brief, psychotherapeutic skills program to prevent and treat symptoms of anxiety and/or depression, according to parent- and youth-report * located in missouri, kansas, or illinois. exclusion criteria: * have significant intellectual disability (iq\<70) or significant expressive or receptive language that would interfere with psychotherapy, according to parent- or youth-report * plans to receive non-study psychotherapy during the course of study participation, according to parent- or youth-report * plans to change current psychoactive or pku-related medication during the course of study participation, according to parent- or youth-report * have active suicidal ideation that would necessitate immediate treatment or require higher level of care than brief psychotherapy, according to parent- or youth-report
evaluation of the efficacy of compression with tight surgical gloves in patients with taxane-based therapy

Conditions: Taxane-induced Peripheral Neuropathy

Summary: in this study, the effect of compression therapy of the hands with tight surgical gloves to reduce peripheral neuropathy in adult patients during the application of taxanes will be evaluated.

chemotherapy-induced peripheral neuropathy (cipn) is a common side effect of treatment with taxanes. the damage to peripheral nerves leads to pain, numbness, and motor dysfunction, which is very distressing for patients and often results in the reduction of the therapeutic dose of taxanes. preventive measures are limited, but recent studies show that compression of the hands with tight surgical gloves can significantly reduce the incidence of cipn. the aim of this randomized controlled trial is to investigate the efficacy of compression therapy in reducing cipn during taxane-based chemotherapy. the randomized controlled and double-blind study will be conducted at the comprehensive cancer center zurich (cccz) of the university hospital zurich from 07/24 to 06/25. participants will be recruited if they have breast cancer or a urogenital carcinoma and are receiving nab-paclitaxel, paclitaxel, or docetaxel. exclusion criteria include previous neurotoxic treatment, existing neuropathy, peripheral vascular disease, or the use of medications that affect polyneuropathy. the intervention group will wear surgical gloves with a compression pressure of 23-32 mmhg (equivalent to compression class ii) for 30 minutes before, during, and 30 minutes after the infusion. the control group will wear non-compressing gloves with a pressure of less than 3 mmhg. the primary endpoint is the occurrence of moderate to severe cipn within four therapy cycles, measured according to nci-ctcae criteria. secondary endpoints include patient-reported symptoms and quality of life, assessed by the fact/cog-ntx questionnaire. comfort and adherence to the compression therapy will also be evaluated. participants will be randomized into two groups of 57 each. data collection and analysis will be conducted according to standardized procedures, and the data will be securely and confidentially stored and managed.

Eligibility criteria:
inclusion criteria: * mamma or urogenital carcinoma * first treatment with taxanes (nab-paclitaxel, paclitaxel, docetaxel) * signed informed consent * sufficient proficiency in german or english exclusion criteria: * other therapy that could have caused peripheral neuropathy within the last 24 months (taxane, platin, vincaalkaloids, etc.) * history of neuropathy such as raynaud's phenomenon, fibromyalgia and diabetic polyneuropathy * use of polyneuropathy medications including duloxetine; gabapentin/pregabalin; topical amitriptyline, ketamine, baclofen; oral cannabinoids; tricyclic antidepressants; and ganglioside monosialic acid * such impaired cognition that prevents participation in the study according to the assessment of the caregivers
patient-partner stress management effects on chronic fatigue syndrome symptoms and neuroimmune process

Conditions: Chronic Fatigue Syndrome

Summary: the purpose of this study is to test the effects of a videotelephone-delivered patient-partner dual-focused cognitive behavioral stress management intervention on chronic fatigue syndrome (cfs) symptoms and related psychosocial and neuroimmune processes in patients diagnosed with chronic fatigue syndrome. study tests the hypothesis that videophone-delivered patient-partner cognitive behavioral stress management (t-pp-cbsm) intervention improves patient cfs symptoms relative to a videophone-delivered patient-partner health information (pp-t- hi) condition.

the study tests the effects of a 10-week patient-partner focused videophone-delivered cognitive behavioral stress management intervention (t-pp-cbsm) intervention (relaxation, stress awareness, cognitive restructuring, coping skills training, interpersonal skills training) versus a time-attention-matched 10-week patient-partner based videophone-delivered health information (t-pp-hi) (health behavior education on nutrition, sleep and other factors) in men and women with chronic fatigue syndrome (cfs) and their partners. the study evaluates the effects of t-pp-cbsm vs t-pp-hi on patient cfs symptoms, neuroimmune processes--diurnal cortisol regulation and immune regulation (pro-inflammatory:anti-inflammatory cytokine ratio (\[il-1β + il-6 + tnf-α\]:\[il-13 + il-10\])-and psychosocial functioning at 5 months and 9 months after intervention.

Eligibility criteria:
inclusion criteria: * men and women diagnosed with chronic fatigue syndrome exclusion criteria: * no partner * prior psychiatric treatment for serious psychiatric disorder (e.g., psychosis, suicidality) * co-morbidity or medical treatment affecting the immune system * lack of fluency in english

Keywords: videophone-delivered stress management intervention chronic fatigue syndrome symptoms neuroimmune processes psychosocial
exploring vancomycin disposition in neonates

Conditions: Neonatal Infection

Summary: vancomycin is already used for decades in neonates. however, there are remaining questions concerning vancomycin disposition in this population. the purpose of this study is first of all to perform a paired analysis of serum vancomycin concentrations using an immunoassay versus a reference liquid chromatography-tandem mass spectrometry method. secondly, we aim to determine vancomycin protein binding and its covariates in neonates.

exploration of vancomycin disposition in neonates: objective 1: paired analysis of (total) serum vancomycin concentrations in neonates using the currently available immunoassay (cobas c702) versus a reference liquid chromatography-tandem mass spectrometry method (lc-ms/ms). objective 2: the determination of vancomycin protein binding and its covariates in neonates.

Eligibility criteria:
inclusion criteria: * neonates, admitted to the neonatal intensive care unit to whom vancomycin is administered for medical reasons, can be included in the study after informed consent of the parents. exclusion criteria: * no vancomycin therapy * no signed informed consent available

Keywords: neonate vancomycin lc/ms-ms protein binding